Insights from 2023 ESMO Asia Annual Meeting
ESMO Asia 2023 Insights: "IMbrave150 Trial - Exploratory Analyses for Investigating Associations Between OS and Depth of Response or Duration of Response in Patients With Unresectable HCC"
Comments 0
Login to view comments.
Click here to Login
